Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SER-214 Safety and PK in Early or Stable Parkinson's Disease
NCT02579473Phase 1Unknown
- Sponsor
- Serina Therapeutics, Inc.
- Start
- Jan 2016
- Primary completion
- Dec 2023
- Modality
- Polymer-based Nanoparticles, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rotigotine polyoxazoline conjugate in Parkinson's disease (PD) (4 cohorts), sponsored by Serina Therapeutics, Inc. Primary endpoints: Safety - Adverse Events and Serious Adverse Events up to 6 weeks, Percentage of patients in each cohort who discontinued therapy due to any adverse events up to 6 weeks and 3 more. Status: unknown.
02
Drugs
rotigotine polyoxazoline conjugate
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02579473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579473.